That's right up AbbVie's alley. The key asset from that transaction, zumilokibart, is being developed to treat eczema. It could also target asthma and eosinophilic esophagitis (a chronic disease that ...

Researchers at The University of Texas MD Anderson Cancer Center have discovered that immunosuppressed patients with ...

Johnson & Johnson Innovative Medicine names Tom Cavanaugh as its next EVP and Worldwide Chairman, succeeding retiring ...

Two newly published papers underscore the need for increased awareness, caregiver education, and preparedness to help ensure timely use of epinephrine during severe allergic reactions ...

There's a change at the helm of Johnson & Johnson's pharma division in the offing, as executive vice president Jennifer ...

BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 ...

Johnson & Johnson named Tom Cavanaugh to lead Innovative Medicine as Jennifer Taubert retires after more than 21 years with J ...

BERKELEY HEIGHTS, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, ...

Lymphocytes are central orchestrators of immune responses, integrating signals from activating and inhibitory receptors, cytokines, and metabolic pathways ...

Molecular biologist Susumu Tonegawa, who made fundamental contributions to immunology and neurobiology and became UC San ...

Macrophages formed in the bone marrow can only assume the function of embryonal phagocytes, or "scavenger cells," to a certain degree according to a study by the University of Bonn and the Peter ...

A massive analysis of immune cells in human tissue is yielding clues to the root causes of lung and autoimmune diseases.